China Media Group Headquarters

Discovering Alshaa Together with the World

Retrieved on: 
Tuesday, September 26, 2023

BEIJING, Sept. 26, 2023 /PRNewswire/ -- "A Bus Tour Across China" is the first mobile bus studio program of the whole network created by the China Media Group. "The Silk Road Journey Season" will set out for Alshaa, on September 27th and 29th, Beijing time. Together with China Media Group Mobile, from Badain Jaran Desert to the poplar forest of Ejin Banner, from Tonghu grassland to Jiuquan Satellite Launch Center etc., audiences can experience the "10,000 possibilities" of Alshaa.

Key Points: 
  • "The Silk Road Journey Season" will set out for Alshaa, on September 27th and 29th, Beijing time.
  • Here, we have the one and only geopark themed on desert in the world: The populus euphratica forest in the Ejina Banner of Alshaa, one of the three largest in the world; and JSLC, one of the world's top three satellite launch centers.
  • The splendid culture, long history, unique landforms, and the world-renowned high-tech achievements are pearls shining on the land of Alshaa.
  • Alshaa, a vast and magical land, locates at the place where Inner Mongolia Autonomous Region, Ningxia Hui Autonomous Region and Gansu join.

CGTN America & CGTN UN: My BRI Stories: share your story!

Retrieved on: 
Friday, September 22, 2023

WASHINGTON, Sept. 22, 2023 /PRNewswire-PRWeb/ -- The Belt and Road Initiative, announced by China in 2013, is marking its 10th anniversary this year. During the past decade, the BRI has seen the expansion of cooperation with a growing number of participating countries and projects.

Key Points: 
  • During the past decade, the BRI has seen the expansion of cooperation with a growing number of participating countries and projects.
  • WASHINGTON, Sept. 22, 2023 /PRNewswire-PRWeb/ -- The Belt and Road Initiative, announced by China in 2013, is marking its 10th anniversary this year.
  • During the past decade, the BRI has seen the expansion of cooperation with a growing number of participating countries and projects.
  • Or do you just want to share your feelings about what it has brought to your country or the world in general?

Transcenta Presented Two Scientific Posters at SITC 2022 Annual Meeting

Retrieved on: 
Friday, November 11, 2022

SUZHOU, China, Nov. 10, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has presented two scientific posters at the 37th Society for Immunotherapy of Cancer's (SITC) Annual Meeting in Boston, MA, November 8-12, 2022.

Key Points: 
  • SUZHOU, China, Nov. 10, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has presented two scientific posters at the 37th Society for Immunotherapy of Cancer's (SITC) Annual Meeting in Boston, MA, November 8-12, 2022.
  • Claudin18.2 staining in 10% of the tumor cells at 1+ or above intensity was present in 216 (72%) tissue samples tested.
  • As of Aug 24, 2022, the first three dose cohorts have been completed and no DLT was observed.
  • Transcenta (HKEX: 06628) is a clinical stage biopharmaceutical company with fully integrated capabilities in antibody-based biotherapeutics discovery, research, development and manufacturing.

Transcenta to Hold 3 Exchange Sessions on Post-SITC Business Update Call & TST003 data release and pipeline development progress update

Retrieved on: 
Wednesday, November 9, 2022

Gremlin1 protein is a highly conserved secreted protein and has shown to play important roles during development.

Key Points: 
  • Gremlin1 protein is a highly conserved secreted protein and has shown to play important roles during development.
  • Transcenta (HKEX: 06628) is a clinical-stage biopharmaceutical company with fully integrated capabilities in antibody-based biotherapeutics discovery, research, development, and manufacturing.
  • Transcenta has also initiated the construction of the Group Headquarters and the second high-end biopharmaceutical facility with ICB as its core technology in Suzhou Industrial Park.
  • Transcenta is developing ten therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders.

Transcenta to Participate in Four Upcoming Conferences

Retrieved on: 
Monday, October 24, 2022

Transcenta (HKEX: 06628) is a clinical-stage biopharmaceutical company with fully integrated capabilities in antibody-based biotherapeutics discovery, research, development, and manufacturing.

Key Points: 
  • Transcenta (HKEX: 06628) is a clinical-stage biopharmaceutical company with fully integrated capabilities in antibody-based biotherapeutics discovery, research, development, and manufacturing.
  • Transcenta has established a global footprint, with Headquarters and Discovery, a Clinical and Translational Research Center in Suzhou, a Process and Product Development Center and Manufacturing Facility in Hangzhou, Clinical Development Centers in Princeton, US, Beijing, Shanghai, and Guangzhou in China, as well as Boston and Los Angeles External Partnering Centers.
  • Transcenta has also initiated the construction of the Group Headquarters and the second high-end biopharmaceutical facility with ICB as its core technology in Suzhou Industrial Park.
  • Transcenta is developing ten therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders.

Transcenta to Present Two Scientific Posters at SITC 2022 Annual Meeting

Retrieved on: 
Friday, October 14, 2022

Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word "cure" a reality for cancer patients everywhere.

Key Points: 
  • Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word "cure" a reality for cancer patients everywhere.
  • Details of the poster presentations are as follows:
    Full text of the abstracts will be released on the SITC website at 8:00 a.m. EST, November 7, 2022, and the posters will be available on Transcenta's website ( https://www.transcenta.com/ ) on November 12, 2022.
  • Transcenta (HKEX: 06628) is a clinical stage biopharmaceutical company with fully integrated capabilities in antibody-based biotherapeutics discovery, research, development and manufacturing.
  • Transcenta is developing ten therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders.

Transcenta Received IND Clearance from FDA for Its Best-In-Class MASP2 Targeting Antibody TST004 for the Treatment of IgA Nephropathy

Retrieved on: 
Wednesday, October 5, 2022

Therefore, inhibition of MASP2 might be a potential treatment approach for diseases related to lectin pathway activation.

Key Points: 
  • Therefore, inhibition of MASP2 might be a potential treatment approach for diseases related to lectin pathway activation.
  • TST004 is a humanized mAb targeting mannose-binding protein-associated serine protease 2 (MASP2) and designed to prevent the inflammation and tissue damage mediated by lectin pathway complement activation.
  • TST004 is a humanized mAb targeting mannose-binding protein-associated serine protease 2 (MASP2) and designed to prevent the lectin pathway complement-mediated inflammation.
  • Transcenta discovered and developed TST004 in-house and plan to develop TST004 for IgA nephropathy (IgAN), a highly prevalent chronic kidney disease with very limited treatment options.

Transcenta Releases Encouraging Interim Safety and Efficacy Data of the TST001 (Osemitamab) and Chemotherapy Combination Expansion Cohort for First Line Claudin18.2 Positive Gastric Cancer at ESMO Congress 2022

Retrieved on: 
Tuesday, September 13, 2022

Based on these encouraging data, the TST001 (Osemitamab) program is further accelerated and Health Authority consultations are being initiated.

Key Points: 
  • Based on these encouraging data, the TST001 (Osemitamab) program is further accelerated and Health Authority consultations are being initiated.
  • A global phase III clinical program of TST001 (Osemitamab) for the first line treatment of locally advanced or metastatic Claudin18.2 positive G/GEJ cancer is currently being planned.
  • These data suggest that TST001 (Osemitamab) in combination with CAPOX as the first line treatment of patients with Claudin18.2 positive G/GEJ cancer is well tolerated and encouraging anti-tumor activities have been observed.
  • "Chemotherapy is still the main treatment of advanced or metastatic G/GEJ cancer, however, it has limited efficacy.

Transcenta Announces the Appointment of Dr. Caroline Germa as Executive Vice President, Global Medicine Development and Chief Medical Officer

Retrieved on: 
Monday, August 8, 2022

Prior to joining Transcenta, Dr. Germa served as the Vice President and Head of the Early Development Clinical Group for AstraZeneca oncology department.

Key Points: 
  • Prior to joining Transcenta, Dr. Germa served as the Vice President and Head of the Early Development Clinical Group for AstraZeneca oncology department.
  • During her time at AstraZeneca, Dr. Germa built an Early Development Clinical Group with over 180 staff and guided the clinical development of the early oncology portfolio.
  • "I would like to express my warmest welcome to Dr. Germa on her appointment," said Dr. Xueming Qian, CEO of Transcenta.
  • I am thrilled to join Transcenta at this important juncture," said Dr. Caroline Germa, Executive Vice President, Global Medicine Development and Chief Medical Officer of Transcenta.

Transcenta to Present Interim Safety and Efficacy Data of the TST001 and Chemotherapy Combination Expansion Cohort for Claudin18.2 Positive First Line Gastric Cancer at ESMO Congress 2022

Retrieved on: 
Thursday, July 28, 2022

TST001 is the second Claudin18.2 targeting antibody therapeutic candidate being developed globally.

Key Points: 
  • TST001 is the second Claudin18.2 targeting antibody therapeutic candidate being developed globally.
  • TST001 kills Claudin18.2 expressing tumor cells by mechanisms of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
  • Leveraging advanced bioprocessing technology, the fucose content of TST001 was significantly reduced during the production, which further enhanced NK cells mediated ADCC activity of TST001.
  • TST001 was granted Orphan Drug Designation in the US by FDA for the treatment of patients with gastric cancer or gastroesophageal junction (GC/GEJ).